Results 71 to 80 of about 19,563 (105)

Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative <i>Klebsiella pneumoniae</i>. [PDF]

open access: yes, 2020
Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam.
Avison, Matthew B   +3 more
core   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

open access: yesJournal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm   +16 more
doaj   +1 more source

Investigating the Effect of Xylitol on ompK36 Overexpression, Increased Meropenem Susceptibility, and Antibiofilm Activity in a Carbapenem‐Resistant Clinical Strain of Klebsiella pneumoniae

open access: yesInternational Journal of Microbiology, Volume 2026, Issue 1, 2026.
Carbapenem‐resistant Klebsiella pneumoniae poses a significant public health threat due to limited therapeutic options. This study investigated the potential of xylitol, a sugar alcohol, to enhance meropenem activity and combat biofilms in a clinical carbapenem‐resistant K. pneumoniae strain (Kp5) and a standard susceptible strain (K. pneumoniae subsp.
Omid Ahlelyorof   +5 more
wiley   +1 more source

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

open access: yes, 2017
Vaborbactam (formerly RPX7009) is a new β-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against K lebsiella p neumoniae
Debora Rubio-Aparicio   +4 more
core   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

open access: yesInternational Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi   +9 more
wiley   +1 more source

Chemical structures of vaborbactam and β-lactams, a monobactam and a DBO inhibitor.

open access: yes, 2021
Vaborbactam, ceftazidime, cefoperazone, meropenem, aztreonam, and zidebactam are represented. The R1-and R2-groups for ceftazidime are indicated.
Vijay Kumar (377076)   +5 more
core   +1 more source

Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance

open access: yesInterdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.
Meropenem is a broad‐spectrum carbapenem antibiotic essential for treating serious infections including urinary tract infections, pneumonia, sepsis, and meningitis. This narrative review examines meropenem resistance trends and prescribing practices for severe infections in Pakistan highlighting how inappropriate use drives local antimicrobial ...
Nasim Akhtar   +7 more
wiley   +1 more source

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

open access: yes, 2018
Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem.
Michael N. Dudley   +5 more
core   +1 more source

Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance

open access: yes, 2023
International audienceAbstract Purpose To demonstrate the feasibility of continuous infusion of meropenem–vaborbactam to optimize the treatment of carbapenem-resistant Enterobacterales.
Larcher, Romaric   +15 more
core   +1 more source

In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii

open access: yesScientific Reports
Treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy